2 reports of this reaction
2.1% of all BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL reports
#17 most reported adverse reaction
MYDRIASIS is the #17 most commonly reported adverse reaction for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, manufactured by CVS PHARMACY. There are 2 FDA adverse event reports linking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL to MYDRIASIS. This represents approximately 2.1% of all 94 adverse event reports for this drug.
Patients taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL who experience mydriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYDRIASIS is a less commonly reported adverse event for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, but still significant enough to appear in the safety profile.
In addition to mydriasis, the following adverse reactions have been reported for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL:
The following drugs have also been linked to mydriasis in FDA adverse event reports:
MYDRIASIS has been reported as an adverse event in 2 FDA reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYDRIASIS accounts for approximately 2.1% of all adverse event reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, making it a notable side effect.
If you experience mydriasis while taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.